Processes for the resolution of benzodiazepin-2-one and benzoazepin-2-one derivatives

Patent metadata

Field	Value
Publication number	US-10851070-B2
Application number	US-201916683303-A
Country	US
Kind code	B2
Filing date	Nov 14, 2019
Priority date	Nov 13, 2017
Publication date	Dec 1, 2020
Grant date	Dec 1, 2020

Abstract

The present invention relates to processes and intermediates useful in the preparation of biologically active molecules, especially in the synthesis of Respiratory Syncytial Virus (RSV) inhibitors. The present invention also relates to processes and intermediates for the preparation of compounds of Formula (I-0) and Formula (I):

First claim

What is claimed:

1. A process for the preparation of a compound of Formula (I-0):

wherein X is N; R 1 is halogen, CN or optionally substituted C 1 -C 3 alkyl; and n is 0, 1, 2 or 3;
said process comprising:
(a) reacting a compound of Formula (I′-0),

with a compound of Formula (III),

wherein R is optionally substituted phenyl, in a solvent selected from acetonitrile, methanol, tetrahydrofuran, 2-methyltetrahydrofuran, ethyl acetate, 1,2-dimethoxyethane, dichloromethane, 1,4-dioxane, toluene, anisole, ethanol, acetone, N,N-dimethylformamide, N,N-dimethylacetamide, pyridine and isopropyl acetate, or a combination of two or more thereof and at a temperature of 20° C. to 45° C., to yield a compound of Formula (IV-0),

provided that said reaction takes place in the absence of an aromatic aldehyde; and
(b) treating the compound of Formula (IV-0) with a base to provide the compound of Formula (I-0).

2. The process of claim 1 , wherein R is

3. The process of claim 1 , wherein step (a) is carried out in a solvent selected from tetrahydrofuran and 1,4-dioxane.

4. The process of claim 1 , wherein in step (b), the base is sodium hydroxide, potassium carbonate, ammonium hydroxide, potassium phosphate tribasic or sodium carbonate.

5. The process of claim 4 , wherein the base is 1N sodium hydroxide, 5 wt % potassium carbonate, 28-30% ammonium hydroxide, 10 wt % potassium phosphate tribasic or 5 wt % sodium carbonate.

6. The process of claim 1 , wherein in step (a) the compound of Formula (I′-0) is present in a mixture with its enantiomer.

7. The process of claim 6 , wherein the mixture is a racemic mixture.

8. The process of claim 1 , wherein n is 0.

9. The process of claim 1 , wherein step (a) is conducted at a temperature of 20° C. to 30° C.

10. The process of claim 1 , wherein step (a) is conducted for 24 to 60 hours.

11. The process of claim 1 , wherein step (a) is conducted for about 24 hours in dioxane at a temperature of 20° C. to 25° C.

12. The process of claim 1 , wherein R is phenyl or phenyl substituted with one or more substituents independently selected from halogen, hydroxyl, C 1 -C 4 -alkyl and halo-C 1 -C 4 -alkyl.

13. The process of claim 1 , wherein R is phenyl.

14. The process of claim 1 , wherein n is 1 or 2 and each R 1 is halogen.

15. The process of claim 14 , wherein each R 1 is fluorine.

Assignees

• Enanta Pharm Inc
• Enata Pharmaceuticals Inc

Inventors

• Hague Andrew
• Ronsheim Matthew

Classifications

• A61K31/5513

  1,4-Benzodiazepines, e.g. diazepam {or clozapine} · CPC title

• C07D243/26 Primary

  Preparation from compounds already containing the benzodiazepine skeleton · CPC title

• C07B2200/07

  Optical isomers · CPC title

• C07B57/00

  Separation of optically-active compounds · CPC title

• A61P31/14

  for RNA viruses · CPC title